ABVC BioPharma is a clinical-stage biopharmaceutical company focused on utilizing its licensed technology to conduct proof-of-concept trials through Phase II of the clinical development process at world-famous research institutions (such as Stanford University, University of California at San Francisco, and Cedars-Sinai Medical Center). The company has an active pipeline of six drugs and one medical device (ABV-1701/Vitargus®) under development.

Company profile
Ticker
ABVC
Exchange
Website
CEO
Howard Doong
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
American BriVision (Holding) Corp, Ecology Coatings, Inc., ECOLOGY COATINGS, INC., METU BRANDS, INC., OCIS CORP
SEC CIK
Corporate docs
IRS number
260014658
ABVC stock data
Latest filings (excl ownership)
424B4
Prospectus supplement with pricing info
15 Nov 22
424B3
Prospectus supplement
15 Nov 22
10-Q
2022 Q3
Quarterly report
14 Nov 22
8-K
Changes in Registrant's Certifying Accountant
21 Oct 22
8-K
ABVC Biopharma Announces Letter to Shareholders
13 Sep 22
8-K
Departure of Directors or Certain Officers
9 Sep 22
424B4
Prospectus supplement with pricing info
25 Aug 22
424B3
Prospectus supplement
25 Aug 22
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
22 Aug 22
10-Q
2022 Q2
Quarterly report
15 Aug 22
Financial summary
Quarter (USD) | Sep 22 | Jun 22 | Mar 22 | Dec 21 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 21 | Dec 20 | Dec 19 | Dec 18 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 1.97 mm | 1.97 mm | 1.97 mm | 1.97 mm | 1.97 mm | 1.97 mm |
Cash burn (monthly) | 543.03 k | 206.64 k | 1.26 mm | 1.54 mm | 171.23 k | 788.49 k |
Cash used (since last report) | 2.28 mm | 869.09 k | 5.29 mm | 6.48 mm | 720.19 k | 3.32 mm |
Cash remaining | -313.79 k | 1.10 mm | -3.32 mm | -4.51 mm | 1.25 mm | -1.35 mm |
Runway (months of cash) | -0.6 | 5.3 | -2.6 | -2.9 | 7.3 | -1.7 |
Institutional ownership, Q2 2022
4.8% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 5 |
Opened positions | 3 |
Closed positions | 2 |
Increased positions | 0 |
Reduced positions | 0 |
13F shares | Current |
---|---|
Total value | 1.66 mm |
Total shares | 1.56 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Armistice Capital | 1.09 mm | $1.16 mm |
Vanguard | 375.14 k | $398.00 k |
Geode Capital Management | 49.92 k | $52.00 k |
BLK Blackrock | 39.04 k | $41.00 k |
Tower Research Capital | 6.00 k | $6.00 k |
Proequities | 0.00 | $0.00 |
News
ABVC BioPharma ABV-1505 ADHD Phase IIa Results Presented At 2023 APSARD Conference
19 Jan 23
Why Spruce Biosciences Shares Are Trading Higher By 100%? Here Are Other Stocks Moving In Friday's Mid-Day Session
6 Jan 23
12 Health Care Stocks Moving In Friday's Pre-Market Session
6 Jan 23
Why Graphite Bio Shares Are Trading Lower By 50%; Here Are 20 Stocks Moving Premarket
6 Jan 23
Dow Falls Over 200 Points; Walgreens Earnings Top Expectations
5 Jan 23
Press releases
ABVC BioPharma ABV-1505 ADHD Phase IIa Results Presented at 2023 APSARD Conference
19 Jan 23
Thinking about buying stock in Bellerophon Therapeutics, Orchard Therapeutics, ABVC Biopharma, KE Holdings, or Vivos Therapeutics?
5 Jan 23
ABVC BioPharma Provides Vitargus® Update - Phase II Vitargus® Study Protocol Received Thai FDA Approval
17 Nov 22
ABVC BioPharma Reports Third Quarter 2022 Financial and Operational Results
14 Nov 22
ABVC BioPharma Receives Notice of Allowance from US Patent and Trademark Office for ABV-1504 Used to Treat Major Depressive Disorder (MDD)
7 Nov 22